The ECE1 Knockout K-562 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human chronic myelogenous leukemia cell line K-562, featuring targeted disruption of the ECE1 gene. This loss-of-function model is produced by introducing CRISPR/Cas9 components to generate a heterogeneous pool of cells with diverse gene-editing outcomes, enabling robust functional studies without clonal isolation. The polyclonal format captures a broad spectrum of knockout events, making it suitable for population-based assays where averaging of phenotypes is desired, and it serves as a versatile tool for investigating endothelin signaling in a leukemic context.
The host cell line, K-562, was originally established from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in blast crisis and is characterized by the presence of the BCR-ABL1 fusion oncogene. K-562 cells display a multipotent hematopoietic progenitor-like phenotype, retaining the ability to differentiate along erythroid, megakaryocytic, and monocytic lineages under appropriate stimuli. Their well-documented growth properties and responsiveness to tyrosine kinase inhibitors such as imatinib make K-562 a standard model for CML research and for studying hematopoietic differentiation and oncogenic signaling.
ECE1 encodes endothelin-converting enzyme-1, a zinc-dependent metalloprotease that functions as a homodimer and localizes to secretory pathway compartments including the Golgi apparatus and plasma membrane. Its primary role is the proteolytic cleavage of big endothelin-1 (big ET-1) to produce mature endothelin-1 (ET-1), a potent vasoconstrictor and mitogen. ET-1 activates the G-protein-coupled receptors ETA and ETB, triggering phospholipase C??-mediated calcium mobilization and downstream cascades such as MAPK/ERK and PI3K/Akt, which promote cell proliferation, survival, and inflammation. ECE1 also processes big ET-2, big ET-3, bradykinin, and substance P, and its expression is regulated by hypoxia and cytokines including TNF-??, IL-1??, and TGF-??, as well as transcription factors AP-1 and NF-??B.
In the K-562 cellular environment, disruption of ECE1 offers a unique opportunity to dissect the contribution of endogenous ET-1 production to leukemic cell biology. Autocrine and paracrine ET-1 signaling has been implicated in cancer progression, and in a BCR-ABL1-driven model, ECE1 knockout allows researchers to evaluate how the loss of ET-1 generation affects proliferation, survival, and differentiation. The interplay between ET-1-mediated signals and oncogenic kinases such as BCR-ABL1 can be systematically explored, providing insights into potential therapeutic vulnerabilities.
These polyclonal ECE1 knockout cells are well-suited for a range of downstream applications, including quantitative analysis of endothelin pathway components via RT-qPCR and western blotting, measurement of secreted ET-1 by ELISA, and functional assays such as MTS-based proliferation tests and Annexin V apoptosis staining. Phospho-specific analysis of ERK and Akt can reveal alterations in signaling dynamics, while imatinib sensitivity assays and flow cytometric assessment of differentiation markers (e.g., CD71, glycophorin A) enable investigation of drug resistance and lineage commitment. Researchers employing this model can explore the role of ECE1 in leukemia progression, vascular biology, and inflammatory signaling. For further technical details and customized solutions, please contact Ascent Research.
